diabetics
Drug Companies Cashing In On Diabetes
Filed in archive News by Rhys on June 30, 2006
Drug Companies Cashing In On Diabetes
Diabetes has become lucrative. The rapid spread of the disease has ensured a big financial opportunity for drug companies looking to cash in on people's misery.

Pfizer Inc. plans to debut Exubra, its new inhaled insulin treatment, in July, and Merck & Co., Novartis AG and Eli Lilly and Co. are awaiting FDA approval for new diabetes products that could generate hundreds of millions of dollars in sales.

"I think it's intensely competitive," said John C. Lechleiter, president and chief operating officer of Indianapolis-based Lilly, which began offering Byetta, an injectable diabetes treatment last year. "Many companies that would not have said they were engaged in diabetes research 10 years ago are squarely there now," he said.

Will this lead to better, more plentiful treatment options? Only time will tell.

(Photo Source: cash advance 101)

Permalink: Drug Companies Cashing In On Diabetes
Tags: exubera  byetta  diabetes  drug  companies  drug+companies  cashing+diabetes  companies+cashing 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/28245
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Drug Companies Cashing In On Diabetes:

  • Currently 8.25/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.25 out of 4 vote(s) cast.
Subscribe
Share It
Popular posts from our other blogs:
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!